Remove Cannabis Remove Compliance Remove DEA Remove Policy
article thumbnail

DEA Promises Progress on Federal Cultivation Applications, But Provides No Timetable for Action

NORML

The US Drug Enforcement Administration (DEA) has once again pledged to take action to better facilitate clinical cannabis research. In 2016, the DEA similarly announced the adoption of new rules to expand to supply of research-grade cannabis, but failed to take any further action.

DEA 163
article thumbnail

Enforcement or Compliance

Canna Law Blog

The War on Cannabis continues through aggressive state and local enforcement and prohibition measures with no end in sight. The issue of enforcement or compliance is probably the biggest one most states face at the policy level. Today, we’ll look at the argument that a compliance focus is better than an enforcement focus.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA Approves CBD-Containing Drug - Will the DEA Finally Step Up?

MJ Business Attorneys

Moreover, the ball is in the Drug Enforcement Agency’s (DEA) court. The FDA can make recommendations to the DEA about substances subjected to scheduling under the CSA, but the DEA is the entity with the power to reschedule CBD. In the recent case Hemp Industries Associations v.

DEA 113
article thumbnail

Press Release: LegitScript Announces New CBD e-Commerce Certification Program to Ensure Accountability, Regulatory Compliance

Cannabis Law Report

Starting today, US manufacturers and merchants can apply through LegitScript to certify CBD products and websites that are in compliance with USDA, FDA, FTC, and DEA regulations, as well as state-specific laws.

article thumbnail

American Bar Association Urges Congress To Let States Set Their Own Marijuana Policies

SMPL

The American Bar Association (ABA) adopted a resolution on Monday that calls on Congress to allow states to set their own marijuana policies and recommends rescheduling or descheduling cannabis under federal law.

Policy 40
article thumbnail

Senators Call For Report On State Of Psychedelic Research

Cannabis Law Report

8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. DEA and the Controlled Substances Act. In addition to the arduous FDA approval process, potential psychedelic therapies would also require complying with requirements from the Drug Enforcement Administration (DEA).

article thumbnail

U.S. Court of Appeals Weighs in on Hemp-Derived Delta-8 THC Classification Cannabis Practice Update

Cannabis Law Report

The first argument was that according to the DEA, Delta-8 remains a schedule I substance because its method of manufacture is “synthetically-derived.” Put simply, regardless of its method of manufacture, if Delta-8 THC is derived from the Cannabis sativa L. plant, it is not synthetic. FOR MORE INFORMATION. 202.263.4128. 202.263.4145.

THC 52